We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Merin, director of the leukemia program at Cedars-Sinai ...
– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...
In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic myelomonocytic leukemia presented at ESMO Congress 2024. Tremblay, an assistant professor ...
BOSTON, Dec. 9, 2024 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...
In observation of Leukemia Awareness Month in September, CURE spoke with an expert about basics of the disease. In observation of Leukemia Awareness Month in September, CURE spoke with an expert about ...
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With ...
The global chronic myelomonocytic leukemia (CMML) market is set for significant growth due to rising CMML cases, advanced targeted therapies, and increased disease awareness. Recognized as a rare ...
Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics, today announced dosing of the first participant in its ...
WICHITA, Kan. (KWCH) - Kansas children battling leukemia have a new hope for survival thanks to a new treatment available in Wichita. KU School of Medicine-Wichita Doctors Nathan Hall and Brian Pate ...
News-Medical.Net on MSN
Groundbreaking tool could transform acute leukemia diagnosis and treatment
Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback